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CHOLELITHIASIS, OR GALL-stone disease, is estimated toaffect between 10% and 15%of the US population, with 1
million new diagnoses yearly.1 Symp-
toms arise in about one third of indi-
vidualswith gallstones, with about 80%
of symptomatic patients experiencing
biliary colic.2 Furthermore, cholecys-
titis usually arises from obstruction in
the cystic duct due to gallstones.3 Cho-
lecystectomy procedures can be a good
proxy indicator for symptomatic gall-
stone disease in clinical research.4 In
2002, therewere 432000 inpatient cho-
lecystectomies performed,5 and the es-
timated total number of cholecystec-
tomies, including laparoscopic
procedures, numbered as high as
770000 in 1996,6 which has been as-
sociated with an expense of more than
$2 billion annually.7
Gallstone formation is thought to rely
on 3 factors: supersaturation of biliary
cholesterol due to hepatic hypersecre-
tion, nucleation of cholesterol mono-
hydrate crystals, and gallbladder hypo-
motility.7,8 The liver has estrogen
receptors, and the presence of endoge-
nous estrogens causes cholesterol satu-
ration in the bile, inhibition of cheno-
deoxycholic acid secretion, and
increased cholic acid content.9 Pro-
gestins inhibit gallbladder contraction,
encourage bile stasis, and have been
shown to decrease the gallbladder’s re-
sponse to cholecystokinin.9 One study
found that exogenous estrogens, given
either transdermally or orally, affected
physiologicmarkers in a pattern that fa-
vored gallstone formation.10
Observational evidence suggests that
estrogen therapy, including the use of
oral contraception and postmeno-
pausal estrogen therapy, is an impor-
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Context Estrogen therapy is thought to promote gallstone formation and cholecys-
titis but most data derive from observational studies rather than randomized trials.
Objective To determine the effect of estrogen therapy in healthy postmenopausal
women on gallbladder disease outcomes.
Design, Setting, and Participants Two randomized, double-blind, placebo-
controlled trials conducted at 40 US clinical centers. The volunteer sample was 22579
community-dwelling women aged 50 to 79 years without prior cholecystectomy.
Intervention Women with hysterectomy were randomized to 0.625 mg/d of con-
jugated equine estrogens (CEE) or placebo (n=8376). Women without hysterectomy
were randomized to estrogen plus progestin (E+P), given as CEE plus 2.5 mg/d of
medroxyprogesterone acetate (n=14203).
Main OutcomeMeasures Participants reported hospitalizations for gallbladder dis-
eases and gallbladder-related procedures, with events ascertained through medical rec-
ord review. Cox proportional hazards regression was used to assess hazard ratios (HRs)
and 95% confidence intervals (CIs) using intention-to-treat and time-to-event methods.
Results The CEE and the E+P groups were similar to their respective placebo groups
at baseline. The mean follow-up times were 7.1 years and 5.6 years for the CEE and
the E+P trials, respectively. The annual incidence rate for any gallbladder event was
78 events per 10000 person-years for the CEE group (vs 47/10000 person-years for
placebo) and 55 per 10000 person-years for E+P (vs 35/10000 person-years for pla-
cebo). Both trials showed greater risk of any gallbladder disease or surgery with es-
trogen (CEE: HR, 1.67; 95% CI, 1.35-2.06; E+P: HR, 1.59; 95% CI, 1.28-1.97). Both
trials indicated a higher risk for cholecystitis (CEE: HR, 1.80; 95% CI, 1.42-2.28; E+P:
HR, 1.54; 95% CI 1.22-1.94); and for cholelithiasis (CEE: HR, 1.86; 95% CI, 1.48-
2.35; E+P: HR, 1.68; 95% CI, 1.34-2.11) for estrogen users. Also, women undergo-
ing estrogen therapy weremore likely to receive cholecystectomy (CEE: HR, 1.93; 95%
CI, 1.52-2.44; E+P: HR, 1.67; 95% CI, 1.32-2.11), but not other biliary tract surgery
(CEE: HR, 1.18; 95% CI, 0.68-2.04; E+P: HR, 1.49; 95% CI, 0.78-2.84).
Conclusions These data suggest an increase in risk of biliary tract disease among
postmenopausal women using estrogen therapy. The morbidity and cost associated
with these outcomes may need to be considered in decisions regarding the use of es-
trogen therapy.
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tant risk factor for gallbladder dis-
ease.8 Observational studies indicate up
to a 2.5-fold increased risk of biliary
tract conditions related to estrogen
therapy.11-16 To our knowledge, the only
previous randomized trial examining
biliary tract outcomes after estrogen
therapy in postmenopausal womenwas
the Heart and Estrogen/progestin Re-
placement Study (HERS), which in-
cluded women with known cardiovas-
cular disease.HERSdata revealed a 38%
increased risk for biliary tract surgery
in the estrogen therapy group.4 Thus,
limited clinical trial evidence is avail-
able to provide unbiased estimates of
the true effects and risks of estrogen
therapy in postmenopausal women.
The Women’s Health Initiative
(WHI) postmenopausal hormone trial
consisted of 2 randomized compo-
nents, in which women with hysterec-
tomy were randomized to receive es-
trogen alone or placebo, and those
without hysterectomy received either
a combination of estrogen and proges-
tin (E+P)or placebo.17 Themajor find-
ings of these trials have been previ-
ously reported.18,19 Together, these trials
represent the largest randomized,
double-blind study of hormone use in
postmenopausal women, and offer the
most reliable and current documenta-
tion of the full risk/benefit profile of the
use of hormone therapy in postmeno-
pausal women. This report provides
new evidence on the effect of estrogen
therapy, with or without progestin, on
gallbladder disease incidence and gall-
bladder surgical outcomes.
METHODS
Participants
This presentation is based on informa-
tion from the estrogen therapy por-
tions of the WHI clinical trials, al-
though 29% were simultaneously
enrolled in the dietarymodification arm
and 59% in the calcium/vitamin D arm
of this complex trial. A detailed discus-
sion of the methods of the WHI trials
and the principal findings of this trial
are available elsewhere.19,20
Womenwere recruited into the trial
at 40 clinical centers, largely via direct
mail. Participants (n = 22579 commu-
nity-dwelling women) were aged 50 to
79 years at the initial screening visit and
they provided written informed con-
sent. The National Institutes of Health
and institutional review boards for all
participating institutions approved the
WHI protocols and consent forms. The
screening and enrollment algorithm is
shown in FIGURE 1.
Women were excluded if they had
any illness that suggested less than a
3-year survival, had a prior cholecys-
tectomy or gallbladder disease, had a
contraindication to using the study
medications, or were deemed to be at
risk of poor medication adherence.
Women with hysterectomy were eli-
gible for the estrogen-alone trial, but
women without hysterectomy were
eligible for the E+P trial due to the con-
cerns about risk of endometrial can-
cer. Eligible participants were random-
ized in equal proportions to receive
estrogen therapy or placebo using com-
puters and a stratified permuted block
algorithm.20,21 Women in the estrogen
alone arm received either placebo or
0.625 mg/d of conjugated equine es-
trogens (CEE) (Premarin;Wyeth, Phila-
delphia, Pa) using blinded dispens-
ing. Women in the E+P trial received
either placebo or 0.625 mg/d of CEE
plus 2.5 mg/d of medroxyprogester-
one acetate, administered as a single
tablet (Prempro; Wyeth).
Reductions in dosage or frequency
were permitted in order to alleviate un-
acceptable adverse effects, although
dosage alterations were generally con-
ducted without unblinding the pa-
tients or study gynecologists. In some
cases, an unblinding officer provided
the clinic gynecologist with the treat-
ment assignment if it was needed due
to safety or symptommanagement. Al-
though the amount of unblinding that
may have occurred with the partici-
pants is unmeasured, the clinic gyne-
cologists were unblinded at rates of
1.9% and 1.5% for the assigned treat-
ment and placebo groups for the CEE
Figure 1. Profile of the Estrogen Therapy Arms of the Women’s Health Initiative
5310 Assigned to Receive
Conjugated Equine
Estrogen
8506 Assigned to Receive
Estrogen Plus
Progestin
8102 Assigned to Receive
Placebo
5429 Assigned to Receive
Placebo
11 941 Had History of
Hysterectomy
and Provided
Informed Consent
18 845 Had No History
of Hysterectomy
and Provided
Informed Consent
342 306 Excluded
2237 Excluded1202 Excluded
1169 Excluded
(Cholecystectomy)
1194 Excluded
(Cholecystectomy)
1198 Excluded
(Cholecystectomy)
1207 Excluded
(Cholecystectomy)
373 092 Assessed for Eligibility
10 739 Randomized 16 608 Randomized
4141 Included in Analysis 4235 Included in Analysis 7308 Included in Analysis 6895 Included in Analysis
Individuals were excluded prior to randomization for safety reasons such as history of breast cancer (4.5%), or
clinic staff impression that a woman was not a good candidate for the study (4.8%). Some women were not
included in the trial if the stratum was closed (4.6%). The majority of exclusions were due to lack of interest or
no informed consent for the estrogen therapy component of the Women’s Health Initiative (81.2%).
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trial, and 40.5% and 6.8% for the E+P
trial. Clinic gynecologists were not in-
volved in the assessment of outcomes.
Study participants were contacted by
telephone 6 weeks after randomization
to assess symptoms and to reinforce ad-
herence. Follow-up for clinical events
was undertaken every 6 months with a
mandatory clinic visit annually. At each
semiannual contact, standardized infor-
mation on specific symptoms and safety
concerns, aswell asmajor health events,
was collected. As described in detail, the
E+P trial was discontinued after a rec-
ommendation from the data and safety
monitoring board concluded that the
overall harms outweighed the benefits
of receiving E+P.19
Study Population, Data Collection,
and Outcomes
The original publication of global find-
ings from the estrogen-alone trial de-
scribed the results for 5310 women in
the CEE group and 5429 in the pla-
cebo group.18 The original publication
of the E+P trial reported the findings of
8506 women receiving E+P and 8102
receiving placebo.19 This total popula-
tion from both hormone studies com-
prise the analytic groups for this re-
port, except that those reporting a
history of gallbladder disease or chole-
cystectomy at entry were eliminated
from the analyses, resulting in the ex-
clusion of 1169 women in the CEE
group and1194 in the placebo group for
the estrogen-alone trial, as well as 1198
women in the active hormone arm and
1207 in the placebo armof theE+P trial.
At baseline, an extensive history was
collected in a standardized fashion us-
ing self-administered forms, inter-
views, andclinical examinations.Weight
and height were measured using a cali-
brated balance beam scale and a wall-
mounted stadiometer. Body mass in-
dex (BMI) was calculated as weight in
kilograms divided by the square of
height inmeters.Race andethnicitywere
self-reported using predefined catego-
ries and were used to explore for treat-
ment effect differences in subgroup
analyses. Other baseline variables, in-
cluding clinical, demographic, social,
and behavioral characteristics, were ob-
tained from self-administered, struc-
tured questionnaires.20
Main Outcome Measures
Gallbladder and gallstone disease out-
comeswere directly reported by the par-
ticipants in the semiannual safetymoni-
toring questionnaire.Whenparticipants
noted any of these outcomes, medical
andhospital recordswere obtainedwith
participant consent. Completion rates
for clinical record acquisition and ad-
judication were estimated overall to be
about 96%. Outcomes used in this
analysis were taken from International
Classification of Diseases-Ninth Revi-
sion and Current Procedural Terminol-
ogy codes. A global outcome for surgi-
cal procedures was constructed to
include all gallbladder and biliary tract
procedures except diagnostic proce-
dures and those that were solely re-
lated to the pancreas; this category in-
cludedCurrent Procedural Terminology
codes (51.0-51.04, 51.2-51.81 and
51.84-51.99). The vast majority of the
procedures were cholecystectomies.
Similarly, a global disease index was
constructed using International Classi-
fication of Diseases-Ninth Revision codes
frommedical and hospital records that
included all designations of acute or
chronic gallbladder inflammation
(574.0-574.2, 574.3-574.41, 574.6-
574.81, and 575.0-575.12) and all gall-
bladder or biliary tract stone disease
(codes 574-574.91). In most in-
stances, participantswith a disease code
also had a procedural code. In all of the
analyses presented here, an individual
in an outcome category is only counted
once, regardless of the number of re-
lated codes present.
Statistical Analyses
This study was a secondary analysis of
a large trial designed and sufficiently
powered to detect clinically relevant
changes in the primary outcomes of
coronary heart disease, hip fracture, and
breast cancer, but the study was not
powered for gallbladder outcomes, as
these were not the primary end points
for the study. Associations between
baseline variables and randomization
assignment were assessed using P val-
ues from 2 tests for categorical vari-
ables and 2-sample t tests for continu-
ous variables. All statistical analyses
were conducted using SAS statistical
software version 9.0 (SAS Institute Inc,
Cary, NC). All outcomes analyses used
time-to-eventmethods andwere based
on the intention-to-treat principle; all
tests used a .05 level of significance.
Outcome comparisons are presented as
hazard ratios (HRs) and nominal 95%
confidence intervals (CIs) from Cox
proportional hazards models, strati-
fied by age, and by the dietary modifi-
cation and/or calcium/vitamin D trial
randomization arm. Since calcium/
vitamin D participants were random-
ized to the calcium/vitamin D trial 1-2
years after randomization in the hor-
mone program, adjustment for calcium/
vitaminD trial participants used the cal-
cium/vitamin D randomization date as
the only time-dependent covariate in
the main analyses. The proportional-
ity assumption was tested by includ-
ing a time treatment interaction term
in the Cox model, in addition to the
treatment indicator. No adjustments
weremade formultiple tests over time,
as this adjustment would be too con-
servative; however, we included a Bon-
ferroni-adjusted 95% CI for multiple
end points. We calculated the number
needed to harm as the reciprocal of the
absolute risk difference between tak-
ing the active drug and control.
Kaplan-Meier plots describe gall-
bladder disease and procedure event
rates over time. Sensitivity analyses ex-
amining the effect of nonadherence
were conducted by repeating these
analyses after censoring events occur-
ring 6 months after a participant be-
came nonadherent (prospectively
defined for adherencemonitoring pur-
poses as consuming 80% of study
pills as determinedbypill count or start-
ing non-study prescribed hormone
therapyduring themost recent 6-month
study interval). Therefore, a treat-
ment indicator was used in the sensi-
tivity analysis as a time-dependent
variable.
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Potential effectmodificationwithpar-
ticipant baseline characteristics includ-
ing recognized gallbladder disease risk
factors was assessed in expanded pro-
portional hazards models that included
the designated risk factor and random-
ization assignment as main effects and
the interaction between them. P values
for possible interactions were com-
puted from likelihood ratio tests, com-
paring models with and without the in-
teraction term. Women with missing
values for the risk factors inagivenanaly-
siswere excluded from the analysis. Sub-
group comparisons were tested for po-
tential effectmodification including age,
BMI, physical activity, prior hormone
or aspirin use, non-aspirin analgesics
use (including nonsteroidal anti-
inflammatorymedicines), or cholesterol-
lowering statins at baseline. Addition-
ally, race/ethnicity subgroups were
examinedwithout statistical testing due
to small numbers in some categories. As
a result, less than 1 of the 7 tests for both
theCEE trial and theE+P trialwould be
expected to be significant at the .05 level
by chance alone.
RESULTS
Baseline characteristics for the entire
study cohort were presented else-
where.17,19 A total of 22579womenwere
analyzed, 8376 in the CEE arm and
14203 in the E+P arm. The proportion
of womenwhowere excluded from the
analysis based on history of a cholecys-
tectomy was higher for the CEE trial
compared with the E+P trial (22.0% vs
Table 1. Baseline Descriptive Characteristics of the Women’s Health Initiative
Characteristics
No. of Participants (%)*
CEE Trial E + P Trial
CEE
(n = 4141)
Placebo
(n = 4235)
E + P
(n = 7308)
Placebo
(n = 6895)
Age at screening, mean (SD), y 63.4 (7.2) 63.5 (7.4) 63.1 (7.1) 63.2 (7.1)
50-59 1309 (31.6) 1346 (31.8) 2502 (34.2) 2354 (34.1)
60-69 1854 (44.8) 1913 (45.2) 3282 (44.9) 3086 (44.8)
70-79 978 (23.6) 976 (23.0) 1524 (20.9) 1455 (21.1)
Race/ethnicity
White 3083 (74.5) 3130 (73.9) 6133 (83.9) 5796 (84.1)
Black 675 (16.3) 726 (17.1) 491 (6.7) 519 (7.5)
Hispanic 217 (5.2) 230 (5.4) 377 (5.2) 319 (4.6)
American Indian 28 (0.7) 26 (0.6) 19 (0.3) 26 (0.4)
Asian/Pacific Islander 77 (1.9) 67 (1.6) 179 (2.4) 156 (2.3)
Unknown 61 (1.5) 56 (1.3) 109 (1.5) 79 (1.1)
Family income, US $
10 000 321 (8.2) 339 (8.5) 359 (5.2) 329 (5.0)
10 000-19 000 750 (19.2) 750 (18.8) 1026 (14.9) 919 (14.1)
20 000-34 999 1168 (29.8) 1133 (28.4) 1902 (27.5) 1745 (26.8)
35 000-49 999 735 (18.8) 794 (19.9) 1462 (21.2) 1382 (21.2)
50 000-74 999 588 (15.0) 592 (14.9) 1222 (17.7) 1213 (18.6)
75 000 353 (9.0) 376 (9.4) 935 (13.5) 929 (14.3)
Education
0-8 y 126 (3.1) 99 (2.4) 162 (2.2) 138 (2.0)
Some high school 260 (6.3) 276 (6.6) 290 (4.0) 293 (4.3)
High school diploma 948 (23.1) 898 (21.4) 1356 (18.7) 1312 (19.2)
School after high school 1722 (42.0) 1832 (43.6) 2898 (39.9) 2585 (37.8)
College degree or higher 1040 (25.4) 1097 (26.1) 2563 (35.3) 2519 (36.8)
BMI, mean (SD)† 29.6 (6.0) 29.7 (6.2) 28.1 (5.7) 28.1 (5.7)
Normal (25.0) 959 (23.3) 933 (22.2) 2375 (32.6) 2273 (33.2)
Overweight (25-30) 1461 (35.5) 1546 (36.7) 2629 (36.1) 2455 (35.8)
Obese (30) 1700 (41.3) 1731 (41.1) 2271 (31.2) 2126 (31.0)
Waist/hip ratio, mean (SD) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1)
Glasses of alcohol/wk
None 535 (13.1) 550 (13.1) 809 (11.1) 783 (11.5)
Past consumption 955 (23.3) 945 (22.5) 1177 (16.2) 1118 (16.3)
1/mo 591 (14.4) 580 (13.8) 1003 (13.8) 931 (13.6)
1/wk 780 (19.0) 830 (19.7) 1466 (20.2) 1277 (18.7)
1-7 wk 836 (20.4) 905 (21.5) 1856 (25.6) 1780 (26.0)
7/wk 402 (9.8) 395 (9.4) 945 (13.0) 949 (13.9)
(continued)
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14.5%, P  .001). The treatment and
control groups were balanced on key
baseline demographic and disease risk
factors (TABLE 1). The only variable that
was significantly different (P .05) be-
tween the placebo and the E+P treat-
ment group was the frequency of mod-
erate to strenuous exercise (Table 1),
although the differenceswere small and
the statistical significancewas driven by
the large number of women enrolled in
the trial. Past or current use of hor-
mone therapy was reported by 26% of
thewomen at the start of the E+P study,
whereas 47% of women with hysterec-
tomy had used hormone therapy. A 3
monthwash-out periodwas required by
current users before being eligible for
randomized treatment assignment.
Among prior hormone users, most use
was of short duration (5y).More than
30% of the participants were obese
(BMI30) and another 36%were over-
weight (BMI 25–30) among women
without hysterectomy, but the women
with hysterectomy had an obesity rate
of 41% with an additional 36% over-
weight.
The estrogen-alone trial was stopped
February 29, 2004, with a mean fol-
low-up period of 7.1 years and a maxi-
mum of 10.2 years,18 with comparable
adherence between the CEE and the
placebo group (57% each). As the E+P
trial was halted early on July 7, 2002,
the mean length of follow-up in this
analysis was 5.6 years for participants
who received placebo and 5.7 years for
participants who received the as-
Table 1. Baseline Descriptive Characteristics of the Women’s Health Initiative (cont)
Characteristics
No. of Participants (%)*
CEE Trial E + P Trial
CEE
(n = 4141)
Placebo
(n = 4235)
E + P
(n = 7308)
Placebo
(n = 6895)
Cups of caffeinated coffee/d
None 1500 (36.5) 1533 (36.6) 2400 (33.1) 2299 (33.6)
1 640 (15.6) 658 (15.7) 980 (13.5) 882 (12.9)
2-3 1404 (34.2) 1378 (32.9) 2622 (36.2) 2484 (36.3)
4-5 416 (10.1) 445 (10.6) 893 (12.3) 884 (12.9)
6 144 (3.5) 172 (4.1) 347 (4.8) 295 (4.3)
Smoking
Never 2117 (51.6) 2099 (50.1) 3584 (49.5) 3409 (50.1)
Past 1557 (38.0) 1635 (39.0) 2887 (39.9) 2672 (39.3)
Current 426 (10.4) 456 (10.9) 770 (10.6) 720 (10.6)
Episodes/wk of moderate
or strenuous activity 20 min
None 817 (21.5) 769 (20.1) 1162 (17.6) 1097 (17.0)
Some 1696 (44.5) 1786 (46.7) 2824 (42.9) 2766 (42.8)
2-4 579 (15.2) 543 (14.2) 1084 (16.5) 983 (15.2)
4 716 (18.8) 727 (19.0) 1518 (23.0) 1618 (25.0)
Hormone use
Never 2189 (52.9) 2210 (52.2) 5397 (73.9) 5132 (74.5)
Past 1445 (34.9) 1466 (34.6) 1417 (19.4) 1336 (19.4)
Current‡ 507 (12.2) 557 (13.2) 491 (6.7) 424 (6.2)
Duration of prior hormone use, y
5 1058 (25.5) 1089 (25.7) 1308 (17.9) 1239 (18.0)
5-10 352 (8.5) 385 (9.1) 372 (5.1) 312 (4.5)
10 542 (13.1) 551 (13.0) 231 (3.2) 211 (3.1)
Duration of oral contraceptive use, y
Nonuser 2524 (61.0) 2624 (62.0) 4124 (56.4) 3939 (57.2)
5 947 (22.9) 909 (21.5) 1699 (23.3) 1489 (21.6)
5-10 375 (9.1) 366 (8.6) 714 (9.8) 700 (10.2)
10 290 (7.0) 334 (7.9) 769 (10.5) 764 (11.1)
Medication use
Nonaspirin analgesics§ 1228 (29.7) 1287 (30.4) 1734 (23.7) 1701 (24.7)
Aspirin 886 (21.4) 911 (21.5) 1565 (21.4) 1521 (22.1)
Statin 305 (7.4) 330 (7.8) 487 (6.7) 428 (6.2)
Abbreviations: BMI indicates body mass index, calculated as weight in kilograms divided by the square of height in meters; CEE, conjugated equine estrogens; E + P, estrogen plus
progestin.
*Subgroup totals may not sum to number randomized because of missing data.
†Means tested on the log scale.
‡A 3-month washout period was required prior to randomization.
§Includes use of acetaminophen, ibuprofen, and other anti-inflammatory medications, but does not include aspirin.
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signed treatment, with a maximum of
8.6 years at the time of trial closure
(TABLE 2). Forty-two percent of those
randomized to E+P and 38% of those
randomized to placebo were noncom-
pliant at some time during the fol-
low-up period.
For the CEE trial, the annual inci-
dence rate for any gallbladder event
(cholecystitis, cholelithiasis, or chole-
cystectomy) was 78 per 10000 person-
years for theCEE group comparedwith
47 per 10,000 person-years for the pla-
cebo group (Table 2). The observed an-
nual incidence rate of any gallbladder
event was 55 per 10000 person-years
for the E+P group, compared with 35
per 10000 person-years for the pla-
cebo group (Table 2). Receipt of both
CEE and E+P significantly increased
the risk for gallbladder procedures,
which were predominantly cholecys-
tectomies (192 in theCEE group vs 104
in the placebo group) (HR, 1.93; nomi-
nal 95% CI, 1.52-2.44; P .001), and
190 cholecystectomies in the E+P vs
107 in the placebo group (HR, 1.67;
nominal 95% CI, 1.32-2.11; P .001).
No association between the random-
ization status and other noncholecys-
tectomy biliary tract procedures was
seen in either trial (27 procedures in the
CEE vs 24 in the placebo group) (HR,
1.18; nominal 95% CI, 0.68-2.04;
P=.56), and 24 procedures in the E+P
vs 15 in the placebo group (HR, 1.49;
nominal 95% CI, 0.78-2.84; P=.23).
Both hormone treatment groups pre-
sented a significant excess risk of both
cholecystitis (HR, 1.80; nominal 95%
CI, 1.42-2.28; P .001 for theCEE trial
and HR, 1.54; nominal 95% CI, 1.22-
1.94; P .001 for the E+P trial), and
cholelithiasis (HR, 1.86; nominal 95%
CI, 1.48-2.35; P .001 and HR, 1.68;
nominal 95% CI, 1.34-2.11; P .001)
for CEE and for E+P, respectively. No
significant interactionswere foundwith
BMI, physical activity, prior hormone
use, or the use of aspirin, non-aspirin
analgesic medicines, or cholesterol-
lowering statins at baseline (all P val-
ues for interaction .20). There was a
suggestion of an increased HRwith in-
creasing age in the CEE trial (P=.06);
however, this association was not seen
in the E+P trial.
The Kaplan-Meier estimates of cu-
mulative hazards of any gallbladder pro-
cedure, any gallbladder disease event,
and the global gallbladder disease or
procedure measure showed a diver-
gence starting in the first year of
randomization, with CEE separating
earlier (FIGURE 2 and FIGURE 3). Bon-
ferroni-adjusted CIs were calculated to
adjust for having multiple end points
in the study, resulting in a 95% Bon-
ferroni-adjusted CI, 1.26-2.21 for the
global gallbladder procedures and dis-
eases; a 95% Bonferroni-adjusted CI,
1.33-2.49 for global gallbladder proce-
dures only; and a 95% Bonferroni-
adjusted CI, 1.34-2.39 for global gall-
bladder diseases for the CEE trial. For
the E+P trial, the results were a 95%
Bonferroni-adjusted CI, 1.19-2.13 for
the global gallbladder procedures and
diseases, 95% Bonferroni-adjusted CI,
1.19-2.24 for global gallbladder proce-
dures only, and 95% Bonferroni-
adjusted CI, 1.20-2.17 for global gall-
bladder diseases for theE+P trial.When
women were censored 6 months after
they became nonadherent to random-
ization assignment in the sensitivity
analysis, the resultant HR for the global
gallbladder procedures and diseases
outcome was 2.19 (nominal 95% CI,
1.65-2.90; P .001) for the CEE trial
(Figure 2D), and (HR, 2.24; nominal
95% CI, 1.71-2.92; P .001) for the
E+P trial (Figure 3D).
COMMENT
TheseWHI findingsdemonstrate, for the
first time in a randomized, double-
blind trial, in otherwise healthy post-
menopausal women, that the risk of
adverse biliary tract outcomeswas sub-
stantially increased by estrogen alone or
E+P, and theHRs for gallbladder events
were similar in the 2 arms. These find-
ings suggest that oral estrogens are caus-
ally associated with gallbladder dis-
Table 2. Incidence (Annualized Percentage) of Gallbladder Disease or Procedures by Randomization Assignment in the Women’s Health
Initiative Estrogen Trials
CEE Trial E + P Trial
Estrogen,
No. (%)
(n = 4141)
Placebo,
No. (%)
(n = 4235) HR (95% CI)
P
Value*
Estrogen,
No. (%)
(n = 4141)
Placebo,
No. (%)
(n = 4235) HR (95% CI)
P
Value*
Follow-up time, mean (SD), y 7.1 (1.6) 7.1 (1.6) 5.7 (1.3) 5.6 (1.3)
Global gallbladder procedure/
disease†
228 (0.78) 143 (0.47) 1.67 (1.35-2.06) .001 228 (0.55) 135 (0.35) 1.59 (1.28-1.97) .001
Global gallbladder procedure 197 (0.67) 113 (0.37) 1.82 (1.45-2.30) .001 196 (0.47) 113 (0.29) 1.63 (1.29-2.06) .001
Cholecystectomy 192 (0.65) 104 (0.34) 1.93 (1.52-2.44) .001 190 (0.46) 107 (0.28) 1.67 (1.32-2.11) .001
Other biliary tract
procedures
27 (0.09) 24 (0.08) 1.18 (0.68-2.04) .56 24 (0.06) 15 (0.04) 1.49 (0.78-2.84) .23
Global gallbladder disease 223 (0.76) 130 (0.43) 1.79 (1.44-2.22) .001 223 (0.54) 130 (0.34) 1.61 (1.30-2.00) .001
Cholecystitis 186 (0.63) 107 (0.35) 1.80 (1.42-2.28) .001 192 (0.46) 117 (0.30) 1.54 (1.22-1.94) .001
Cholelithiasis (gallbladder
or biliary calculi)
197 (0.67) 110 (0.36) 1.86 (1.48-2.35) .001 208 (0.50) 116 (0.30) 1.68 (1.34-2.11) .001
Abbreviations: CEE indicates conjugated equine estrogens; E + P, estrogen plus progestin; CI, 95% confidence intervals; HR, hazard ratios.
*P values from Cox proportional hazards analyses stratified by age and randomization status in the Women’s Health Initiative Dietary Modification and Calcium and Vitamin D trials.
†Events include the first of any diagnosis of gallbladder disease including cholecystitis or calculi, as well as biliary tract procedures, including cholecystectomy.
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eases, and themagnitude of the effect is
not influenced greatly by the presence
or absence of progestins. These find-
ings are in the same direction, but of a
greater magnitude, than the findings of
theHERS, the only other large random-
ized controlled trial of this therapy,
which showed a 38% increase in hospi-
talizations for gallbladder disease over
4.2 years follow-up amongwomenwith
known cardiovascular disease at en-
try.4 Biliary tract surgerywasmore com-
mon in HERS participants, although,
with7%of those randomized to theE+P
arm having surgery vs 5% of the pla-
cebo group, and the effect of E+P ap-
peared to diminish over time. The find-
ings of the present study suggest that the
risk continues to increasewith longer ex-
posure to E+P.
Estrogens appear to influence sev-
eral key steps in gallstone formation.
One study of postmenopausal women
found that exogenous CEEs given
orally, or estradiol given transderma-
lly, decreased nucleation time in vitro,
increased cholesterol saturation in-
dex, and increased biliary arachido-
nate and prostaglandin E2 levels.10 The
authors asserted that this pattern of
findings resulted in both an increased
propensity to form cholesterol crys-
tals and an excess saturation of biliary
cholesterol,10 which along with hypo-
motility of the gallbladder are thought
to be key requirements for gallstone for-
mation.7,8 The effect of estrogen therapy
has also been studied in men who re-
ceived exogenous estrogens. In an au-
Figure 2. Kaplan-Meier Estimates of Cumulative Hazards for Any Gallbladder Outcomes in the Estrogen-Alone Trial
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CEE indicates conjugated equine estrogens; CI, confidence interval; HR, hazard ratio. Procedure (A) or disease (B) among women receiving CEE or placebo. Any gall-
bladder disease or procedure during follow-up was used to comprise a global index (C). A sensitivity analysis was conducted with censoring occurring at 6 months after
nonadherence with randomization assignment (D).
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topsy study of men randomized to es-
trogen therapy for the treatment of
prostate cancer, the rate of cholecys-
tectomy was higher, but the preva-
lence of cholelithiasis among estrogen
users was lower at time of death.22
Prior observational studies have ex-
plored the role of estrogen therapy in
gallbladder disease, dating as far back as
1974.23 TheNurses’ Health Study found
an increased risk of cholecystitis among
participants taking exogenous estro-
gens, with a relative risk of 2.1 for cur-
rent hormone users, with higher risks
associated with longer duration of use
and greater doses.11 The Atherosclero-
sis Risk in Communities study group
found that former and current hor-
mone users had a significantly in-
creased risk of hospitalized gallbladder
disease (relative risk, 1.76 for current us-
ers and 1.84 for former users), and this
effect persisted in multivariate models
including age, race, and BMI.13 Mam-
dani et al found that Canadian women
who recently started using estrogen
therapy had a 1.9 age-adjusted relative
risk for cholecystectomy.14However, not
all studies have found increased risk for
gallstone disease. One small case-
control study of 200 women found no
significant excess odds for gallstone sur-
gery amongwomen using estrogen.15 A
cross-sectional study of 1765 Danish
women reported an association be-
tween estrogen therapy and gallstones
detected by ultrasound, but this asso-
ciation did not persist in multivariate
analyses.16
Figure 3. Kaplan-Meier Estimates of Cumulative Hazards for Any Gallbladder Outcomes in the E + P Trial
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CI indicates confidence interval; E + P, estrogen plus progestin; HR, hazard ratio. Procedure (A) or disease (B) among women receiving E + P or placebo. Any gallbladder
disease or procedure during follow-up was used to comprise a global index (C). A sensitivity analysis was conducted with censoring occurring at 6 months after non-
adherence with randomization assignment (D).
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The WHI study results provide
strong evidence of a causal associa-
tion between estrogen therapy and gall-
stone disease because randomized trials
are the best study design to provide un-
biased estimates of effect. Nonethe-
less, some limitations of the study
should be acknowledged. The gener-
alizability of these findings is limited to
mostly healthy postmenopausalwomen
who took part in the WHI, and who
were selected for willingness to com-
ply with the treatment regimen. Thus,
a “healthy volunteer” effect may ex-
plain the low overall rate of gallblad-
der disease in this study comparedwith
other studies, although the random-
ized design verifies the internal valid-
ity of the effects of CEE and E+P in this
study. The exclusion ofwomenwith re-
ported disease at baseline was con-
ducted post hoc, although the num-
bers were comparable between the
randomized groups. Also, the baseline
prevalence of disease was significantly
higher among the women with hyster-
ectomy (22% vs 14% of women with-
out hysterectomy), and the incidence
rates remained higher in the women
with hysterectomy throughout the fol-
low-up period. Changes in BMI may
also have an effect on gallbladder out-
comes, as both obesity and rapidweight
loss are thought to contribute to gall-
stone formation, and estrogen therapy
and a history of hysterectomy are as-
sociatedwith greater BMI. In this analy-
sis, we conducted a subgroup analysis
to test for differences in treatment effect
depending on baseline BMI and found
no significant interaction. However, we
did not adjust for changes in BMIwhile
using the study medication, because
weight changemay be part of the causal
pathway between estrogen therapy and
gallbladder disease.
Another potential sourceof bias could
result from differential noncompliance
to the study drug, if adverse effects in
the treatment groups were more likely
than among the placebo group. This
problem is unlikely to strongly influ-
ence the results because the noncom-
pliance rates were similar between the
active hormone and the placebo users
for both trials and the statistical analy-
sis was performed within an intention-
to-treat framework. When participants
were censored at 6 months after non-
compliance in the sensitivity analysis, the
estimated effects of the active hor-
moneswere increasedongallbladderdis-
ease outcomes due to the reduction in
“crossover” or misclassification be-
tween the groups.
Ascertainment bias may be a threat
to the findings, if estrogen users in both
trials were more likely to have diag-
nostic suspicion of gallbladder disease
when compatible symptoms emerged.
We cannot fully rule this out, but think
it is unlikely for several reasons. First,
our trial findings are consistent with
prior observational data. Also, the blind-
ing appeared to work well across the
trial until vaginal bleeding caused by the
active drug supervened in some par-
ticipants, who thenmay have been un-
blinded. The unblinding rates for the
clinical gynecologists were higher for
the active hormones in both trials, al-
though the E+P trial had a substan-
tially higher unblinding rate. How-
ever, the clinic gynecologists were not
involved in the assessment of out-
comes. It was not possible to deter-
mine the proportion of participantswho
were indirectly unblinded based on
their perceptions of randomization sta-
tus. We believe that vaginal bleeding
would not lead to enhanced surveil-
lance for gallbladder disease. In in-
stances where symptoms may have
caused study drug discontinuation, the
results would have been biased to-
ward the null hypothesis. The sensi-
tivity analysis, which censored indi-
viduals after 6months after study drug
noncompliance, revealed an increased
risk of the outcome among estrogen
therapy users. Also, the primary trial
findings for E+P showed that some con-
ditions were less commonly found in
the treatment group, including colon
cancer. We feel that these findings ar-
gue against biases from differential un-
blinding and ascertainment.
Finally, the findings for this study
cannot necessarily be extrapolated to
other types of estrogen therapy and
other routes of administration. Fur-
ther study is needed to help deter-
mine if transdermal administration of
estrogen therapy has the same effect on
biliary tract outcomes, since the first
pass effect would be lessened.
In summary, this large randomized
trial showed an important increase in
gallbladder disease and surgical proce-
dures among women who were ran-
domized to using either oral CEE or
E+P. Among women with hysterec-
tomy, CEE contributed to 78 events per
10000 person-years, which is 31 ex-
cess events per 10000 women annu-
ally. In the E+P trial, there were 55
events per 10000 person-years, which
is an excess of 20 events per 10000
women annually. The number needed
to harm,which is the number ofwomen
who would undergo the interventions
in 1 year in order to cause 1 excess ad-
verse gallbladder outcome, were cal-
culated to be 323 for CEE and 500 for
the E+P arms. Thewomen in this study
were not selected to have preexisting
cardiovascular disease as was the case
in the HERS, and were geographically
dispersed across 40 clinical sites. There-
fore, these results should bemore gen-
eralizable to healthy postmenopausal
women in the United States without
previous gallbladder disease and less
likely to be biased than observational
study cohort data. The increased risk
for gallbladder events should be ad-
dressed in the decision-making pro-
cess for women considering meno-
pausal hormone therapy.
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